Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research report issued on Tuesday, February 25th. Zacks Research analyst E. Bagri ...
Innovation in HIV care and prevention is transforming the fight, but there is more to be done in order to meet the UNAIDS targets of ending the HIV epidemic by 2030 ...
When asked about each segment of ESG, almost all of the surveyed groups, 94%, said that the impact a pharma has on society is important to them. The “G” came in second place, with 88% saying a company ...
Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.
The Juilliard-trained talent said he's honored to get the gig: "Our queer siblings across the country who are being unfairly ...
Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...
Salesforce's outlook fell short of analysts’ expectations, sending shares lower in extended trading Wednesday.
Salesforce is expected to report fourth-quarter results after the market closes Wednesday, with analysts largely bullish on ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corp. (SCHW), ...
Three bovine veterinarians had undetected H5N1 avian influenza infections despite no apparent contact with infected cows, ...
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback